Place Your BETs in Combination Therapy

Brian J Liddicoat; Mark A Dawson

doi:10.1016/j.molcel.2020.05.026

Place Your BETs in Combination Therapy

Mol Cell. 2020 Jun 18;78(6):991-993. doi: 10.1016/j.molcel.2020.05.026.

Authors

Brian J Liddicoat¹, Mark A Dawson²

Affiliations

¹ Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3052, Australia.
² Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3052, Australia; Centre for Cancer Research, University of Melbourne, Melbourne, Australia. Electronic address: mark.dawson@petermac.org.

PMID: 32559426
DOI: 10.1016/j.molcel.2020.05.026

Abstract

Combination therapy remains the cornerstone for cancer management, and understanding how to rationally partner drugs is imperative. In this issue of Molecular Cell, Shu et al. (2020) provide a tour de force multi-omic approach to identify synergistic pathways that increase the efficacy of BET bromodomain inhibitors in triple-negative breast cancer.

Publication types

Comment

MeSH terms

Antineoplastic Agents*
Humans
Nuclear Proteins
Triple Negative Breast Neoplasms*

Substances

Antineoplastic Agents
Nuclear Proteins